8th February, 2016

The General Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001
Scrip Code: **500770**

National Stock Exchange of India Ltd.
Exchange Plaza
Bandra-Kurla Complex
Bandra (E)
Mumbai 400 051
Symbol: **TATACHEM**

Dear Sir,

Sub: Intimation under Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR) Regulations

This has reference to the intimation made by our subsidiary, Rallis India Limited ('Rallis'), informing that the Board of Directors of Rallis has approved the increase in the stake in Metahelix Life Sciences Ltd. (Metahelix), subsidiary of Rallis, from 80.51% to 100%. Consequently, Metahelix will become a wholly owned subsidiary of Rallis on completion of the acquisition of the balance shares in Metahelix.

A copy of the intimation letter from Rallis to the stock exchanges in this regard is enclosed herewith for your reference.

This is for your information and records.

Thanking you,

Yours faithfully,
For Tata Chemicals Limited

(Rajiv Chandan)
General Counsel & Company Secretary

a.a. Enclosed

RALLIS INDIA LIMITED

Corporate Identity No. L36992MH1948PLC014083

2nd Floor Sharda Terraces Plot No 65 Sector 11 CBD Belapur Navi Mumbai 400 614
Tel 91 22 6776 1657 Fax 91 22 6776 1775 email pmeherhomji@rallis.co.in

Mrs P S Meherhomji
Company Secretary

5th February, 2016

The General Manager
Corporate Relationship Dept.
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Asst. Vice President
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra - Kurla Complex
Bandra (E)
Mumbai 400 051

Dear Sir,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We wish to inform you that the Board of Directors of the Company, at the their Meeting held on 5th February, 2016, has approved increase of the Company's stake in Metahelix Life Sciences Ltd. (Metahelix), subsidiary of the Company, from 80.51% to 100%. Consequently Metahelix will become a wholly owned subsidiary of the Company, on completion of the acquisition of the balance shares in Metahelix.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated 9th September, 2015 are given in the enclosed Annexure.

Thanking you,

Yours faithfully
RALLIS INDIA LIMITED

(P. S. MEHERHOMJI)

Encl.: a/a

RALLIS

ANNEXURE

Rallis to acquire balance stake in Metahelix to go to 100%

Sr. No.	Details of Events that need to be provided	Information of such event(s)
1.	Name of the target entity, details in brief such as size, turnover, etc.	Metahelix Life Sciences Ltd. ***(MLS)***
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length".	No
3.	Industry to which the entity being acquired belongs.	Seeds
4.	Objects and effects of acquisition (including but not limited to disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	Acquisition done in accordance with the Share Holder Agreement dated 9th December, 2010 entered into at the time of the initial acquisition
5.	Brief details of any governmental or regulatory approvals required for the acquisition.	Not required/Applicable
6.	Indicative time period for completion of the acquisition.	February 2016
7.	Nature of consideration - whether cash consideration or share swap and details of the same.	All cash

.....2/-

RALLIS

<table>
<tr><td>8.</td><td>Cost of acquisition or the price at which the shares are acquired.</td><td>Total consideration of Rs.73.33 crores</td></tr>
<tr><td>9.</td><td>Percentage of shareholding/ control acquired and/ or number of shares acquired.</td><td>19.49%</td></tr>
<tr><td>10.</td><td>Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief).</td><td>MLS a Seeds Company with a strong Research background with facilities in in Bangalore, Hyderabad & Ahmedabad including many testing locations across the country. MLS has a good product portfolio in rice, maize, millet and vegetable seeds along with good germplasm with many products in the pipeline. The audited financials of MLS for last 3 years are as follows:
Rs. crores
<table>
<tr><th>Particulars</th><th>FY 12-13</th><th>FY 13-14</th><th>FY 14-15</th></tr>
<tr><td>Revenue from operations</td><td>141.86</td><td>224.81</td><td>309.99</td></tr>
<tr><td>PAT</td><td>0.95</td><td>9.23</td><td>16.52</td></tr>
</table></td></tr>
</table>